Novartis Says European Commission Approved Cosentyx for Polymyalgia Rheumatica Treatment

11:36 AM EDT, 10/21/2026 (MT Newswires) -- Novartis (NVS) said Wednesday that the European Commission has approved Cosentyx for the treatment of adults with polymyalgia rheumatica, a common inflammatory rheumatic disease, characterized by acute pain and stiffness in the shoulders, neck, and hips. The recommended dose for Cosentyx is 150 mg by subcutaneous injection with initial dosing at weeks zero to four, followed by monthly maintenance dosing in combination with a tapering course of glucocorticoids, Novartis said. Additional regulatory reviews of Cosentyx in polymyalgia rheumatica are ongoing in US and Japan, Novartis further said. Price: 153.54, Change: -0.10, Percent Change: -0.06